TABLE 2—
Treatment Exposure, Serious Adverse Events, and Outcomes by Treatment Condition: New Haven, CT, March 2015–December 2016
| Variable | CBT4CBT plus TAU (n = 43), No. (%) or Mean ±SD | TAU Only (n = 49), No. (%) or Mean ±SD | Total (n = 92), No. (%) or Mean ±SD | df | f or χ2 | P |
| Treatment exposure | ||||||
| D in treatment (max = 56) | 47.7 (14.4) | 41.7 (16.8) | 44.5 (15.9) | 1,90 | 3.45 | .07 |
| No. of urine specimens collected (max = 8) | 6.3 (2.3) | 6.7 (2.1) | 6.5 (2.2) | 1,87 | 0.50 | .48 |
| % of expected urine specimens collected | 79.3 (28.5) | 83.3 (25.8) | 81.5 (27.0) | 1,87 | 0.50 | .48 |
| No. of individual sessions | 2.8 (2.6) | 2.9 (2.5) | 2.9 (2.5) | 1,90 | 0.01 | .91 |
| No. of group sessions | 2.4 (3.9) | 5.2 (6.6) | 3.9 (5.7) | 1,90 | 6.04 | .02 |
| Total no. of case management sessions | 0.6 (1.4) | 1.1 (3.4) | 0.9 (2.7) | 1,83 | 0.60 | .44 |
| No. of medical services | 1.0 (1.0) | 1.0 (1.0) | 1.0 (1.0) | 1,83 | 0.04 | .85 |
| No. of psychiatric services | 1.3 (1.2) | 0.9 (0.8) | 1.1 (1.0) | 1,83 | 3.51 | .07 |
| No. d took medication for psychiatric problems | 39.2 (22.3) | 38.3 (22.5) | 38.7 (22.3) | 1,83 | 0.03 | .86 |
| Serious adverse events | ||||||
| Participants with ≥ 1 SAEs, psychiatric or substance use related | 3 (7) | 2 (4.1) | 5 (5.4) | 1 | 0.37 | .54 |
| Participants with ≥ 1 SAEs, medical issues | 1 (2.3) | 3 (6.1) | 4 (4.3) | 1 | 0.79 | .37 |
| Secondary substance use outcomes | ||||||
| % days abstinent from primary drug during treatment, self-report | 76.9 (24.7) | 62.2 (37.6) | 69.0 (32.9) | 1,87 | 4.54 | .04 |
| % urine specimens negative for all drugs | 42.9 (44.5) | 37.4 (41.4) | 39.9 (42.7) | 1,87 | 0.37 | .54 |
| % positive breathalyzer tests | 2.8 (15.8) | 6.3 (19.6) | 4.7 (17.9) | 1,87 | 0.84 | .36 |
Note. CBT4CBT = computerized cognitive behavioral therapy plus treatment as usual; SAE = National Institutes of Health–defined serious adverse event within treatment; TAU = treatment as usual.